Standard definition for all spectrum of myocardial ischemia/threat or "Heart Attack" are well established [9] [10] [11] [12] [13] [14] . With the advent of diagnostic tools predominately biomarkers the definitions of "Heart Attack" has also evolved 9 . Similarly with the kidneys, the advent of renal injury biomarkers call for a new paradigm in AKI or "Kidney Attack". The lack of symptoms and delays in conventional AKI markers highlight a greater impetus for this term "Kidney Attack" within such a framework as we have highlighted. It is also stressed that injury and function in the renal and cardiac sense or not synonymous. In addition physiological differences highlight that injury is not always associated with loss of function and vice versa. It is thus important we introduce the term "attack" to categorize stages of heightened risk that may or may not be associated with early renal functional decline. Bio = cardiac or renal biomarkers; EF = ejection fraction , surrogate for cardiac function; EKG ST = electrocardiogram ST segment; MI = myocardial injury/ infarction; N = Normal; RF = Renal Function; RI = renal injury/infarction; ST segments; Th = Thrombus; Sym = symptom; UO = urine output; ↑ increased; ↓ = decreased; ↓ = Trend; + = positive; -negative; ± equivocal 
Two clinical pathways are shown. Chest pain pathways are well established. Renal pathways are less well established. Urine output and SCr provide surrogate information on renal function. With the advent of AKI biomarkers, clinicians now have the ability to anticipate renal injury, with or without functional changes, as early as 2 hours from the insult. With more specific and comprehensive renal injury and function information we also begin the paradigm of reclassification the spectrum of "acute kidney syndromes". We have chosen the term "Kidney Attack" as it highlights firstly the urgency involved and secondly there are correlations with the lessons learnt from the heart. We emphasize that the role of AKI biomarkers are still partly in the research domain, and so to our understanding of "acute kidney syndromes". As such the schema proposed, has a degree of conjecture, however we feel that significant impetus is needed to highlight renal injury risks and as such the severity of the "Kidney Attack". We have chosen NGAL from the spectrum of renal biomarkers as it remains the most likely candidate for a "Renal Troponin". Renal injury biomarkers have a broader pathogenic base than serum troponin, for those discussion we point readers initially to Ref history for ACS). Because AKI does not cause visceral discomfort, the concept of Renal Angina (RA) or pathophysiologic stress on the kidneys, the parallel of cardiac angina, has been introduced in order to provide a similar construct to help direct the use and interpretation of AKI diagnostics [5] . Renal angina is currently undergoing validation in prospective studies of adults and children.
Thus, a new nomenclature for 'kidney attack' and AKI related syndromes with a wider spectrum of clinical criteria (clinical AKI, subclinical AKI, and renal angina) could be used for classification purposes (Figure 1 and Figure 2) [6] [7] [8] [9] [10] [11] [12] . The parallels between the terminology used in ACS and AKI is intentional, as we hope to use these familiar and accessible terms to help teach the non-experts how to appropriately integrate these new terms into the clinical vernacular. The public health burden of AKI is substantial. The population incidence of AKI is approximately 2,100 per million population and the case fatality rate is 25-50% [6] . Given the population of the developed world (USA, Canada, Western Europe, Japan, and Australia) of approximately 1 billion, there will be over 2 million cases of AKI this year, with 500,000 associated deaths and an expected 1.5 million AKI survivors. Of these patients, approximately 15-20% will progress to advanced stage CKD within 24 months, resulting in 300,000 cases of advanced CKD per year. With the increasing incidence of AKI in the aging population, the projected incidence of CKD associated with AKI is expected to increase [7, 8] .
In conclusion, the advances in consensus definitions and diagnostic biomarkers in AKI have led to an evolution in the nomenclature of the syndrome. Similar to the progress made in ACS and the lay term 'heart attack' , AKI and 'kidney attack' hold promise. We believe that an educational campaign for awareness and alertness should be undertaken to prevent and improve early recognition of 'kidney attack' with use of novel, approved biomarkers and careful assessment of urine output. We think that the new terminology centered around 'kidney attack' will provide uniformity in the public health approach to AKI, and help to reveal what has been neglected and underestimated for too long simply because it was not clinically detectable.
